Blend CJC 1295 NO DAC 5mg with Ipamorelin 5mg

Blend CJC-1295 NO DAC 5MG with Ipamorelin 5MG is a powerful combination of two synthetic peptides, designed specifically for use in in vitro experiments studying growth and development. Both peptides are analogs of human growth hormone-releasing hormone (GHRH) and share the first 29 amino acids of the 44-amino-acid sequence found in GHRH, retaining its biological properties.^(1,2)

Animal studies have shown that CJC-1295 and Ipamorelin significantly increase growth hormone (GH) release compared to control groups.^(2,3) Furthermore, CJC-1295 has been reported to enhance the release of insulin-like growth factor 1 (IGF-1) in various animal models.⁽⁴⁾ Research on Ipamorelin indicates that it supports normal bone formation and structure. An 8-week study in rats demonstrated significant increases in bone mineral content following the administration of Ipamorelin, GH, and related peptides, as confirmed by post-mortem bone scans.⁽⁵⁾

CJC-1295 exhibits superior pharmacokinetic and pharmacodynamic properties compared to intrinsic GHRH. The modification of the amino acid sequence in CJC-1295 NO-DAC prevents degradation by peptidase enzymes, thereby enhancing peptide stability in in vitro experiments.⁽⁶⁾

The combination of CJC-1295 and Ipamorelin impacts multiple physiological systems, including GH release, metabolism, immunity, insulin regulation, and cell differentiation. This makes it a valuable tool for investigating growth and metabolic disorders in a controlled laboratory environment.

These peptides are synthesized, combined, and distributed strictly for research purposes only. They are not intended for human consumption, medical use, or any application outside of laboratory research. Improper use can be harmful to humans.

This combination is provided as a white lyophilized powder, with a concentration of 10 mg per vial (5 mg of each peptide).

References:

1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.
2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.
3. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8.
4. Campbell RM et al. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides. 1994;15(3):489-95.
5. Svensson J et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77.
6. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8.